The Myeloma Beacon » MAGE-A3 and NY-ESO-1 Immunotherapy

MAGE-A3 and NY-ESO-1 Immunotherapy

By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled

Brand Name:
Generic Name:
Code Name:	MAGE-A3 and NY-ESO-1
Company:	University of Arkansas
FDA Clinical Phase:	2/3

Description:

The purpose of MAGE-A3 and NY-ESO-1 immunotherapy is to generate anti-myeloma T-cells (natural immune system cells) to kill myeloma cells and nothing else.

Clinical Trials:
For a list of clinical trials studying MAGE-A3 and NY-ESO-1 immunotherapy for the treatment of multiple myeloma, see ClinicalTrials.gov ^[1].

Source: ClinicalTrials.gov, Multiple Myeloma AND MAGE-A3, http://www.clinicaltrial.gov/ct2/show/NCT00090493?term=multiple+myeloma+AND+MAGE-A3&rank=1 ^[2] (as of September 4, 2008)

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2008/10/15/mage-a3-and-ny-eso-1-immunotherapy/

URLs in this post:

[1] ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/results?cond=multiple+myeloma&intr=MAGE-A3

[2] http://www.clinicaltrial.gov/ct2/show/NCT00090493?term=multiple+myeloma+AND+MAGE-A3&rank=1: http://www.clinicaltrial.gov/ct2/show/NCT00090493?term=multiple+myeloma+AND+MAGE-A3&rank=1

Click here to print.